Swan-Ganz vs Impella: When to Use Each
A Swan-Ganz (pulmonary artery) catheter should be used for hemodynamic monitoring and shock phenotyping in cardiogenic shock, while an Impella device should be used when you need active mechanical circulatory support to unload the left ventricle and augment cardiac output—these are complementary tools, not competing alternatives.
Understanding the Fundamental Difference
These devices serve entirely different purposes and are not interchangeable:
- Swan-Ganz catheter: A diagnostic and monitoring tool that measures hemodynamic parameters (cardiac output, pulmonary artery pressures, wedge pressure, mixed venous oxygen saturation) without providing therapeutic support
- Impella device: A therapeutic mechanical circulatory support (MCS) device that actively pumps blood from the left ventricle to the aorta, providing 2.5-5.0 L/min of flow depending on the model 1
When to Use a Swan-Ganz Catheter
Use a pulmonary artery catheter in the following scenarios:
Primary Indications
- Complex shock phenotyping: When you need to determine if shock is LV-dominant, RV-dominant, or biventricular to guide device selection 2, 3
- Refractory shock despite initial therapy: Patients not responding to vasopressors and requiring escalation of support 2
- Guiding MCS device selection: Use hemodynamic parameters like PAPi (pulmonary artery pulsatility index) and cardiac power output to determine which MCS device is appropriate 4, 3
- RV failure assessment: Essential when RV dysfunction is suspected, as the PAC measures pulmonary artery pressures that guide therapy 2
- Severe ARDS with shock: Particularly valuable for guiding fluid therapy in patients with moderate-to-severe ARDS and shock 2
Evidence Supporting PAC Use
Recent meta-analyses demonstrate mortality benefit: PAC use in cardiogenic shock is associated with a 30-37% relative reduction in mortality (OR 0.63-0.70) 5, 6. Specifically in STEMI patients treated with Impella, PAC use was associated with 20% lower in-hospital mortality (adjusted OR 0.80) without increasing complications 7.
The 2025 ESICM guidelines suggest using PAC "in complex patients to determine the type of shock" and "in patients with severe shock especially with associated ARDS" 2. The evidence shows PAC enables better therapeutic decision-making, including appropriate MCS device selection 4, 8.
Key Hemodynamic Parameters to Guide Decisions
- Cardiac power output <0.6 W: Indicates need for MCS escalation 3
- PAPi <1.0: Suggests RV failure requiring RV-specific support 3
- PCWP >15 mmHg with RA >15 mmHg: Indicates biventricular failure 3
When to Use an Impella Device
Deploy Impella for active hemodynamic support in these situations:
Primary Indications
- Cardiogenic shock requiring mechanical support: When medical therapy (vasopressors, inotropes) fails to maintain adequate perfusion 1
- High-risk PCI: Prophylactic support during complex coronary interventions 1
- AMI-related cardiogenic shock: Particularly when early revascularization is planned 9
- Postcardiotomy shock: When unable to wean from cardiopulmonary bypass 10
Device Selection Based on Support Needs
- Impella 2.5: Provides 2.5 L/min; may be insufficient for large BMI patients or severe shock 1
- Impella 5.0: Provides 5.0 L/min; requires surgical cut-down but offers more robust support 1
- Impella RP: Specifically for RV failure 4
Critical Limitations
The evidence for mortality benefit with Impella is weak. Compared to IABP, Impella provides superior hemodynamic support but no difference in 30-day mortality 1. The IABP-SHOCK II trial showed no mortality benefit for routine IABP use in AMI-CS 9, and this finding likely extends to other MCS devices given the lack of randomized data showing mortality benefit.
Complications to Monitor
- Bleeding
- Thrombosis
- Limb ischemia
- Hemolysis 1
The Complementary Approach: Using Both Together
The optimal strategy often involves using BOTH devices simultaneously:
- Insert PAC first to establish baseline hemodynamics and shock phenotype 3, 8
- Use hemodynamic data to determine if MCS is needed and which device is appropriate 4
- Deploy Impella if cardiac power output <0.6 W or persistent hypoperfusion despite medical therapy 3
- Continue PAC monitoring after Impella insertion to:
Evidence supports this combined approach: Studies show PAC use with Impella is associated with lower mortality 7, and shock teams that use standardized protocols with hemodynamic parameters see improved outcomes 4.
Common Pitfalls to Avoid
Don't Make These Mistakes:
- Deploying Impella without hemodynamic assessment: You may select the wrong device or miss biventricular failure requiring different support 3
- Assuming Impella eliminates need for PAC: The PAC remains essential for ongoing assessment and guiding therapy escalation 8, 6
- Using Impella in irreversible shock: Patients without reversible causes or transplant candidacy won't benefit from temporary MCS 4
- Delaying PAC in complex shock: Early hemodynamic data improves decision-making and outcomes 2, 5, 6
Specific Contraindications:
- For Impella: Severe aortic insufficiency, LV thrombus, mechanical aortic valve, severe peripheral vascular disease 1
- For PAC: Severe coagulopathy (relative), tricuspid mechanical valve (absolute)
The Reality of Current Practice
Despite weak guideline recommendations for PAC use 11, contemporary evidence increasingly supports its value. PAC use in cardiogenic shock has been rising (from 25.9% to 41.8% between 2016-2020) 7, while outcomes data consistently show mortality benefit 5, 6. The disconnect between older ICU trials (which showed no benefit) and contemporary CS registries (which show benefit) likely reflects improved shock team protocols and better integration of hemodynamic data into clinical decision-making 8, 12.
The bottom line: In 2025, best practice involves using PAC for hemodynamic assessment and phenotyping, then deploying Impella (or other MCS) based on those data when mechanical support is needed. These are complementary tools that work best together, not competing alternatives 4, 3, 7.